Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pulmonary Arterial Hypertension Pulmonary Hypertension 18 years or older. 2. Diagnosis of WHO Group 1 PH (Pulmonary Arterial Hypertension, PAH) evidenced by all the following parameters measured at rest: 1. Mean pulmonary artery pressure (mPAP) ≥25 mmHg; 2. Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤15 mmHg; 3. Pulmonary vascular resistance (PVR) >3 Wood units. 3. Patient remains symptomatic despite being on a stable drug regimen of at least two PH specific medications for at least 90 days prior to planned index procedure. 4. Patient with a current assessment of WHO Functional Class (FC) III. 5. Main pulmonary artery (MPA) diameter and anatomy suitable for placement of the device as defined in the Instructions For Use (IFU) and as assessed by multi-slice computed tomography (MSCT). 6. Patient is deemed appropriate for Aria CV device by the Patient Care Team at the investigation site and approved by the Central Screening Committee (CSC). 7. Patient understands the study requirements, is willing and able to provide appropriate informed consent and is committed and able to attend all required follow-up visits and undergo all required tests at the clinic  Diagnosis of WHO PH Groups 2, 3, 4 or 5. 2. Patient with recent clinical events of any of the following: 1. Myocardial infarction or stroke within 6 months prior to the index procedure; 2. Sustained tachyarrhythmia (documented heart rate >110/min) within 2 months prior to the index procedure. 3. Any pre-existing or requirement of emergent surgery/ intervention, or implantation of prosthetic cardiac device that may interfere with Aria CV device placement or function (e.g. pulmonary or tricuspid valve repair or replacement, pacemaker, defibrillator, inferior vena cava filters, neurostimulators, drug infusion devices, etc.). 4. Patient with any of the following medical history or comorbidities: 1. History of endocarditis; 2. Current renal insufficiency as demonstrated by a serum creatinine > 2.0 mg/dL or end stage renal disease requiring chronic dialysis; 3. Current scleroderma, or other collagen vascular disease treated with immuno-suppressant; 4. Current pulmonary veno-occlusive disease (PVOD); 5. Current pulmonary capillary hemangiomatosis (PCH); 6. History of clinically significant patent foramen ovale or other inter-atrial or inter-ventricular shunt; 7. History of gastric antral vascular ectasia (GAVE), gastrointestinal or intracranial bleeding which, in the opinion of the investigator, will predispose subject to major bleeding events following Aria CV device placement and warfarin anticoagulation regimen; 8. Current active systemic infection requiring antibiotic therapy; 9. Blood dyscrasias that may, in the opinion of investigator(s), expose patient to unacceptable procedural risks such as severe or worsening leukopenia, anemia, thrombocytopenia, untreated iron deficiency or history of bleeding diathesis or coagulopathy. 5. Anatomy not suitable for placement of Aria CV device, including 1. No suitable subcutaneous implantation location for the reservoir; 2. Contraindication to 22 Fr venous access via a subclavian vein; 3. Body habitus that precludes safe placement of any components of the Aria CV device. 6. Right heart valve regurgitation: 1. Moderate to severe (Grade 3 or 4) pulmonary valve regurgitation; 2. Severe (Grade 4) tricuspid valve regurgitation. 7. Hypersensitivity or contraindication to 1. Required medications (e.g. contrast agents, warfarin, heparin) which cannot be adequately managed; 2. Materials in device including polyurethane, silicone, nickel, and titanium. 8. Patient ineligible for or refuses blood transfusion. 9. Pregnant or lactating female or planning a pregnancy during participation in the study. 10. Patient with life expectancy of less than two years. 11. Currently participating in or planning to participate in other investigational drug or device trials that may interfere with the outcome of this study